Radnor Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.3M | Sell |
9,442
-225
| -2% | -$230K | 1.59% | 8 |
|
|
2026
Q1 | $8.89M | Hold |
9,667
| – | – | 1.32% | 14 |
|
|
2025
Q4 | $10.4M | Sell |
9,667
-340
| -3% | -$325K | 1.54% | 9 |
|
|
2025
Q3 | $7.64M | Sell |
10,007
-150
| -1% | -$112K | 1.16% | 16 |
|
|
2025
Q2 | $7.92M | Hold |
10,157
| – | – | 1.26% | 11 |
|
|
2025
Q1 | $8.39M | Buy |
10,157
+20
| +0.2% | +$16.6K | 1.41% | 10 |
|
|
2024
Q4 | $7.83M | Sell |
10,137
-2,174
| -18% | -$1.8M | 1.31% | 11 |
|
|
2024
Q3 | $10.9M | Buy |
+12,311
| New | +$11.1M | 1.62% | 9 |
|
|
2024
Q2 | – | Sell |
-10,536
| Closed | -$8.2M | – | 238 |
|
|
2024
Q1 | $8.2M | Sell |
10,536
-225
| -2% | -$160K | 1.4% | 10 |
|
|
2023
Q4 | $6.27M | Sell |
10,761
-1
| -0% | -$584 | 1.17% | 12 |
|
|
2023
Q3 | $5.78M | Buy |
+10,762
| New | +$5.55M | 1.15% | 11 |
|
|
2023
Q2 | – | Sell |
-6,681
| Closed | -$2.29M | – | 199 |
|
|
2023
Q1 | $2.29M | Buy |
6,681
+2,039
| +44% | +$688K | 0.6% | 40 |
|
|
2022
Q4 | $1.67M | Sell |
4,642
-6
| -0.1% | -$2.13K | 0.41% | 68 |
|
|
2022
Q3 | $1.5M | Sell |
4,648
-372
| -7% | -$118K | 0.44% | 67 |
|
|
2022
Q2 | $1.63M | Sell |
5,020
-290
| -5% | -$87K | 0.45% | 69 |
|
|
2022
Q1 | $1.52M | Buy |
5,310
+352
| +7% | +$90.6K | 0.38% | 79 |
|
|
2021
Q4 | $1.37M | Buy |
+4,958
| New | +$1.26M | 0.34% | 77 |
|
|
2021
Q3 | – | Sell |
-5,420
| Closed | -$1.24M | – | 159 |
|
|
2021
Q2 | $1.24M | Sell |
5,420
-490
| -8% | -$98.4K | 0.42% | 61 |
|
|
2021
Q1 | $1.1M | Hold |
5,910
| – | – | 0.36% | 71 |
|
|
2020
Q4 | $998K | Buy |
5,910
+150
| +3% | +$22.4K | 0.28% | 76 |
|
|
2020
Q3 | $853K | Sell |
5,760
-300
| -5% | -$46.4K | 0.29% | 78 |
|
|
2020
Q2 | $990K | Sell |
6,060
-200
| -3% | -$30.7K | 0.36% | 66 |
|
|
2020
Q1 | $868K | Sell |
6,260
-450
| -7% | -$61.8K | 0.36% | 64 |
|
|
2019
Q4 | $882K | Hold |
6,710
| – | – | 0.27% | 82 |
|
|
2019
Q3 | $750K | Hold |
6,710
| – | – | 0.25% | 92 |
|
|
2019
Q2 | $743K | Sell |
6,710
-500
| -7% | -$58.9K | 0.24% | 94 |
|
|
2019
Q1 | $936K | Sell |
7,210
-1,900
| -21% | -$231K | 0.31% | 78 |
|
|
2018
Q4 | $1.05M | Sell |
9,110
-310
| -3% | -$34.6K | 0.38% | 64 |
|
|
2018
Q3 | $1.01M | Sell |
9,420
-405
| -4% | -$40.5K | 0.32% | 76 |
|
|
2018
Q2 | $838K | Sell |
9,825
-150
| -2% | -$12.3K | 0.31% | 80 |
|
|
2018
Q1 | $772K | Hold |
9,975
| – | – | 0.26% | 85 |
|
|
2017
Q4 | $842K | Sell |
9,975
-190
| -2% | -$16.2K | 0.27% | 86 |
|
|
2017
Q3 | $837K | Hold |
10,165
| – | – | 0.28% | 80 |
|
|
2017
Q2 | $837K | Hold |
10,165
| – | – | 0.28% | 80 |
|
|
2017
Q1 | $855K | Hold |
10,165
| – | – | 0.29% | 79 |
|
|
2016
Q4 | $748K | Buy |
+10,165
| New | +$757K | 0.26% | 87 |
|
Other funds holding LLY
Radnor Capital Management's LLY Position: Q2 2026 in Review
Radnor Capital Management reduced its Eli Lilly (LLY) stake by 2.3% in Q2 2026, selling an estimated $230K and leaving 9,442 shares worth $11.3M. The position accounts for 1.59% of the portfolio, ranked #8.
Radnor Capital Management first reported a position in LLY in Q4 2016 and has held it in 36 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Radnor Capital Management held 9,442 shares of Eli Lilly worth $11.3M as of Q2 2026.
- Radnor Capital Management sold 225 Eli Lilly shares in Q2 2026, an estimated $230K.
- Eli Lilly made up 1.59% of Radnor Capital Management's portfolio in Q2 2026, its #8 holding.
- Radnor Capital Management first reported a position in Eli Lilly in Q4 2016 and has held it in 36 quarters since.
- 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Radnor Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.